213 related articles for article (PubMed ID: 25310726)
1. Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome.
Shmueli MD; Schnaider L; Herzog G; Gazit E; Segal D
PLoS One; 2014; 9(10):e109864. PubMed ID: 25310726
[TBL] [Abstract][Full Text] [Related]
2. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
[TBL] [Abstract][Full Text] [Related]
3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
4. Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis.
Hsouna A; Nallamothu G; Kose N; Guinea M; Dammai V; Hsu T
Mol Cell Biol; 2010 Aug; 30(15):3779-94. PubMed ID: 20516215
[TBL] [Abstract][Full Text] [Related]
5. Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network.
Leonardi E; Murgia A; Tosatto SC
FEBS Lett; 2009 Nov; 583(22):3704-10. PubMed ID: 19878677
[TBL] [Abstract][Full Text] [Related]
6. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
Corn PG; McDonald ER; Herman JG; El-Deiry WS
Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
[TBL] [Abstract][Full Text] [Related]
7. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
Biochem Biophys Res Commun; 2002 Jun; 294(3):700-9. PubMed ID: 12056827
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
11. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
12. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions: implications for its physiological activities.
Sutovsky H; Gazit E
J Biol Chem; 2004 Apr; 279(17):17190-6. PubMed ID: 14963040
[TBL] [Abstract][Full Text] [Related]
14. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
Aso T; Yamazaki K; Aigaki T; Kitajima S
Biochem Biophys Res Commun; 2000 Sep; 276(1):355-61. PubMed ID: 11006129
[TBL] [Abstract][Full Text] [Related]
15. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
17. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
19. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
20. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
